Utilizing cytology and ovarian cancer xenograft (PDX) models, Zhang et al. demonstrated that for sensitive ovarian cancer cells, BET inhibitors specifically suppressed FoxM1 and its subsequent targets by cell cycle block, while c-MYC expression was just temporarily downregulated and then returned to baseline levels. Here, MYC is linked to ovarian carcinoma.